This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
7/,'a,Jt
I
SuuuRv, Apnrr 22, 2001
7:00-9:00 p.m. ElnLy RrcryRmot't
MouoRY, ApnlL 23, 200 |
Foyer - Regency Balhoom E/F
Wttcotvrr AND INTRoDUCTToNs Regency Ballroom E/F$/illiam J. Martone, M.D.Nationa| Foundatictn.fbr Infecticttts Diseases
lH Mmonram - Cnanus Mrnrrux, 1907-2001: lH nr TnlorrroH or PmrruRSten l t ' y A . P lo t k in . M .D .At;entis PasteurLh itt e rs it! oJ' P e t t n s.y I u a n i a
pro|i f ic,composionote,ondrourogeousvotcino|ogist '0nSeptember2,]99B0r'Ciements' i i1onnondherhusbondJona*on}rtonn,M,D.perishedinthecflightllloffthecoostofNovosrolio,[onodo. FormoreinformotiononDr.0ements-Monn,visitwww.nfid.org,/ronferences/wrcine01/tlementyd4onn.
Th e .[r,t h rt s Hctpki n s [ht it,ers i t-1, S c lt oci ct' Pt ilt / i c Hea / tltN. Regina Rabir-rovich, M.D.P rogra m .f o r Approp t^i ate Te cb t rctl og,y i rt Hectlth
lrssons rRoM THE Rouvrnus Vaccrlr: AH 0vrnutw or rnr lssursF. Marc LzrForce, M.D.Basic Support.lbr Instittltiortctlizing Child Sunitlal (BASICS il)
Qursrrous lt lo AHswrRs
lrssons tRoM THr Ronvrnus VaccrHr: [rxlclr CoHsrornalolsChlistine Grady, R.N., Ph.I).National Institutes of Health
QursrroHs nuo At'tswrns
A Ntw GrurnaroH or (rnrrrlors ron ltrrnHATtoNAL Rrsmnct EurcsJames V. Lavery, M.D.lYationctl lrtstittttes of Health
0ursrrotls lruu Arswrns
LuncH
Assrssrtlo lmmutloroe rc Rrspol'rsr AND DtsEAsE Pnorrcrror'rModerators: Gregory A. Poiand, M.D.
,,, Mayo Clinic artd Founclation, Ethan M. Shevacl'r, M.D.
t' Nntional Institutes oJ'Health
Regency Bullroom t
Post-rxposunr [)NA Vlccrualon Pnorrcrs Mrcr AolrHsr Rltrrs Vrnus.D. Lodmell* and T. Ewalt.Roch,y Moutfiain la;boratories, NIAID, Hamilton, MT.
(04 T fttts Tnatsrtnnm rnom VP6-nruuNrzrD 0R Nrivr Mrcr Wrnr rHr 0uLy Lyr'rpHocwrsNirorn':,lo ilrsowt Rornvtnus Stmotno rn (HRotlrcrLLy Inrrcrro Rnc-2 Mrrr.R,L, \X/ardn, M.M. McNeal, J.A. Fl int. J.L. VanCott,and A.H-C. Choi.Cbildren's HospftAl Medical Center, Cincinnati, OH.
2100 p.rn. 52.
I
2:15 p.m.
2:30 p.m.
2:45 p.m. s5.
3:00 p.m.
s4.
53. Lolo-Itnm Ertrcts or n NovtL ItposomnL eD Vacctrur ou Mrr,rrr,lrzrr,rc InrnavaolrunL Hrnprs SrupLrx VrnusI t ' trrclot 'r t t t Mtcr.R. M:.rsotrcl*r, L.H. Songr,\7. ELnstr, G. Fr-rjir, ancrJ.p. Aciler-Moorer.'cctl Pcl.1, fittit,ttsi{r,, p()nt(ttta, (A. :Moleculttr Eryress ntc., Los AtryeJes, cA.
(worrrur Rrsporusr lr,r HuLrHy ltrarurs ArrrR MmsLrs VlrtrHlrton.I .G. orsyrrrrnik ' ru" ' . l t .M.. ] r rcolrson. K.C. Reic l . A.L. oberg. L.K. Lcdelr t r l r r .G.G. KIee, ar-rcl G.A. poland.
Trr (ylotlrur Rrspotlsr ForLowrruo Hrparrrrs A lml,tururznloru.M.S. Hayney"', and.f.M. Buck.LIt t it'e rc it.1' ctf' wis c ort s i r t s c h ool of- ph ct rm a c.y. Macl i s o r t, rilT.
Toncs rr'r Vnmrmny AND HuMAN Vaccruorocy Regency Eslhoon E
3:15 p.m.
Su gi,rttttnPntsttrltnttor,ts 2:(Concurrent Session)
I 145p.m.
Moderutors: Peter L. Nam, D.V.M. ph.D.B iologica I Mi n rct ics I t t c.tl;,tl,l,l;:,Tih;,f,
,t,','r"rh4rectiousD,seases
57. UBITH (rr,,t) Sylrnrrrc Prprror Vrcclrlr ron FMDV ru Swrlr.A. Walfield"'r. F. Slrenr.J yel. E. Kramerr. M.yehr.J.Lubrothr,C.Y. Wangr. F. Blown-.tLhzited Biornedical, Inc., Hauppauge. hv rUSDA plu,m IslarzdAttintal Disease Center Greenpofi, Ny.
58. DtvrLopmtnt or Llvr Anrrourtro Vnccmrs roR [oulur lHrrcrrous Aurlara Vrnus (gAV).F. Lir" ' . B. Pufferr. K. Hennessy', c.rsser3. and R. Monteraror.tLlnit'ersit.v of Pittsburgb, pitt.sburgb, pA; rlnteruet Inc., Merriant, KS;:(Jttiuersit.V of Kentuckv, [-exington, Ky.
2:00 p.m.
2:15 p.m.
3:15 p.m.
SusMrnrnPnrsrrumnous 3:(Concr:rrent Session)
l:45 p.n.
2:{5 p.m. st t .
59. THr DrvrLopmtltt or Bnono Srrcnuu PuLsro Lronr (BSPL) ns rnr (nrrrcnL luncrrvlrror'r Srrpron rur MlNurA(rttRt of Vncot'trs.\7.H. Cover*, J. Hollow,ly, NI. Lzrnders ancl K. Salisbuty.Ptrre Pulse Tecbnolctgies, Ittc.. Sctrt Diego, CA.
DNA hurtlunullt0N wrltt pop3 GrHr or (HLnmvou rRA(H0MATIs lr'ursrrs rHr SpRrnu or (HumyoraL
lurtcltou rRoM rHr Lowrn ro rnr Upprn GrurrnL Tucr rn (3H/HrN FrrruLr Mrcr.R. Cevenini'', V. Sambri, M. Don:rti, K. Di Leo, M. Com:rnducci, ancl G. Ratti.Llnittersit.)t of-Bolctgttct, Bctlogna, Ital.r,; Chiron Vaccirtes, Siertct. Itctl-y.
D0D-Wtor SunvttLLnncr ron ltL-HIlLtH Rroutntuo Hosprrnrrzarror'r Porrt.trmLLy Assocrnrro wtrn At'trnuxlmmunrzlrrorl: I 998 Dnrn.P.A. Sato'', T.C. Smith, RJ. Reed, L.Z. Wang.l,lctt,al Healtlt Research Center, Satt Diego, CA.
(ontr Bnar
sr0.
sr2.
Cunnrt'tr Toprcs rN VA(crNoLoGYModerators: Diane E. Griffin, M.D., Ph.D.
Washington Room
513.
Tlt e ./oh tts Hopkirts Lht iuersit.r, Sch ool of Pt t blic HectltbN. Regina Rabinovich, M.D.Program Jbr Appropriate Tecbnctlog1t itt Healtb
lnrrrrclrvrHrss 0f IflE (ttRRrNr Srnarroy r0 PRrvrNT Hrpnrrrrs A n TnnvrLLrns.G. De SelTes*l'1, B. Duval1z, R. Shadmani2, N. Bouliannel r, G. Pol-nniJ, M.Naus3, M. Douville Fradetl*, BJ. Ward5, K.C. Kain('.
sl4.
' tlnstitr.tt National de Sante Publique du Quebec, Quebec;2Laual Llttitten;itil,Qwebec;3OntarbMinistty of Healtb and Long-Ternt Care, Tctronto;4Ministdre de Ia Sant€ et des Setaices Sociaux du Quebec, Quebec; tMontreal
: General Hospital, Montreal;6L/niuercity of Toronto, Toronto.
Sl5. Errtclcl, lililulrosn'ucln AND SAFrry 0r THr MAIARTA Vaccrur RTS, 5/58A502: Ar'r 0vrnvrrw.frJ, {$1niepofth*, K, Boiang, l. Vigneron, M. Pincler, P. Milligan, O. Ofbri-Anyinam. T. Doherty, M. Delchambre. K.E. Kester'. D.G. Heppner'.K. McAdam, B.M. Greenwood. A.V.S. Hill. and J. Cohen.GlaxoSmitbKline Biologicals. Rixensart. Belgi t t nt.
2:15 p.m.
2:30 p.m.
2:45 p.m.
3:00 p.m.
3:15 p.m.
Svmposrum 2:
3:45 p.m.
4:10 p.m.
4: l5 p.m.
4:40 p.m.
4:45 p.m.
5:10 p.m.
5:15 p.m.
Sl6. YnLow Fwm (YF) l/D VrRus rs I Lrur Vrsor ron NovrL [Hrmrrur Vaccrr.lrs ([HrrlmVaxrM]: Pututlrcn nrun fuuluL ExpmuucrT.P. Monzrti-r'". J. Aloyo, K. Pugache-\', K. McCarthy, P. Beclforcl. ancl
F. Gr-r i l r rk lroo.Acu t t t bis I t tc'.. Ca t t r lu'id,qt'. XM.
Ttr SlclurclHc or lmmuHoroercar Mrrurcny FoR THr Drvnopmrur or Nru VlcclHlrtoN SrnnrrcttsRolrcr t S. Ftr l inami. PIr .D.Ll t t i t'ers i t.t' qf Llta h Sc h r r t I o.l' M ecl i c i t t e
0ursrror,rs AND ANswtRs
Auro-lmmuHrTy RtsutlNc tnom BysrauDtR l i lmuilot0cl(Al I trtcrsEthan M. Sl-revach, M DNational Institute of Atterg and.Infectiotts Diseases
Qursltorus ano Aruswrns ' ,
lHrrcnlrro Appnonctts ro Asstss mo ltmr tru Rlsr ol Auto-lmmuur Aovrnst ElrtcrsPaul-Henri Lambert, M.D.L/ n i t'c rs i t.v of Geneua
Qursrrotls luo AHswtRs
Porrnrnr Yl(cNATtot,Appnotcxts ro Pnrvrtr on Tntlr Auro-lmuuur DtsrlsrsDavid C. \fraith, Pli.D.Llniuercity of Brisrot
5:40 p.m.
5:45 p.m.
6:00 p.m.
7:00 p.m.
0ursrrorus lno AuswrRs
AniouRnurrur
Atnrnl B. Snnln Vlcctr'rr ltsrrrurr
Pnrsruurror,r oF THE A$rRT B. SlsrN
Rrcrpttot't
GoLo Mmnr
Woshington Room
Regency Bollroom E/F
Tursonv, Apnlr 24, 2001
7f-FF-l-t-I
l-fIF-f-lrililililrarril
ilaiara-
n!l
nIIrt;l
trnEf
f
f
;l
f
ttl
;l
;l
;rnlrf,
I
7:00-8;00 o.m.
7:30 o.m.
Svttlposrull 3:
8:00 o.m.
8:25 n.m.
8:30,u.m.
8:55 o.m.
9:00 o.m.
9:25 r,m;
?:30 u.rn:
Rrcnnalou
(ot'tttt'ttttuL B nrnrmy
Vaccrr'rrs Acnltsr Mauenmon AND CttRoNtc DsmsrsModelators: Jacques Banchereau, ph.D.
Foyer - Regency Bollroom E/F
txhibn uallt
Regency Ballroom E/F
Baylor Institute Jbr Intnutnologt ResearcbMyron M. Levine, M.D., D.T.P.H.[Jtt it'te rc i ty oJ- M a ryv la nd S c b o o I of' Me d i c in e
A Vaccli l t ton Utctns l lo Glsrntc ( lHcrn: A Rarrotnrr roR AN H. pvrcntVlccrlrJulie Parsonnet, M.l).Starford Llnittetsity Scbool of Medicine
,0ursrtous llo Answrns
VEcclnrs Aoaltsr ArxrnoscrrnoslsCarl R. Alving, M.D.Walter Reed Army Institute of Researcb
QuesrroHs aHo AHswrns
Antlunro HInpts Smrux Vtnus Vlcclxr Snrr [xpnrssrne l[-l2 ln rHr Ttmlpv or GuomnsRichard J. Whirley, M.D.Uttiuersit.y of Alabama at Birmingbam Scbool of Medicirte
Qursnous aHo Answrns
Upolrr ox Duonrrrc (rrr VlccrnlsJacques Banchereau, ph.D.Ba.ylor Insti tute for Imm u n ology Resea rc b
9:55 o.m.
l0:00 o.m.
SusMrilmPnrstrutnttor'rs 4:(Concurrent Session)
l0:30 o.m. Sl9.
l0:45 o.m. S20.
I l:00 a.m. 52 | .
I l: l5 o.m. 522.
I l:30 o.m. S23.
()mrnvro AND HypoTHrlcAl ADVERSE Evrrun Asocwru t,v[H VAcctNEs
Qunnotls mo Answrns
(orrrr Bnur/Poyrn Snsror,r/Exnrws txhihit HullA
Regency Ballraom FNloderators: Vill iant.f. Maltone, M.D.
hutictttttl Forr ttdatiotr .for Ittfectious DiseasesV i l l i l r n M . E g l n . P l r . l ) .Li.S. Foocl ancl Drug Adrninisttwtiott
lruclutttct ntlo (LtucnL Pnrsrutnttotl or a Nrw OcuLo-RrspruroRy Syr,roRour Assocrnrru wrrH lrurrurlza VnccrNr.N. Bouliannel r, G. l)e Serres'*r I, B. Duv:rl1r, R. Shlrdmanir, ancl L. Rochette2.tlttstitttt l{cfiional de Sant€ Pttblique du Quebec, Quebec;
2laual Lfnittercity,
Qtrebct'.
THt Inctotucr or 0cuLo-RtspruioRv SvruuRomr (0RS) n HmLm (rnr Wonrrns Forrowrue lrurruruznVlccttutror't.D. Skowlonski*r, D. MacDonaldr, E. Husainr, J. Mzrcnabbr, E. Galanisr, A.Kingi, R. Parker* and P. Dal1,i"'BC Centre For Disease Contrctl; ')BC Children's Hospital; sDiuision ofIntmunizatictn, Health Canada; 'sinton Fraser Heotltb Reg1iott: tVartcortuer
Richntond Health Regiott.
luvtsttoltton or au 0curnn-RrsprnnroRv Svnonomr Assocrnrro wrrn lurLurwzt lmuururzlrroH, (lulol, 2000.E. Galanisr - , A. K ing" ' i . L . Palkonyay ' . C. Dubuc 'and t l te Oculo-Respi ratoryWolking Group.tDit'isiotr oJ'lntnttrttizaliott. Health Canada; '/Field Epidemiologlt TruittittgProgrant. Healtb Cattada: rVaccittes Diuision, Health Canada.
(nanncttntzlt toH or Euooorruous AvrAN Lrurosrs Vrrusrs rn n (nrcr FrsnolLlsr SusslRnrr Usro rH rnrPnouucrotl or Mtnsrrs luo Mut, lps Vnccrlr.J.A. Johnson"' and W. Heneine.Certters fot' Disease Cctttt rol and Preuention. Allanta. GA.
Slrttv nHo Totrnastutv 0t lNrruINZA Vrnus VnrrrHr, Tnrvarrnr, Iyprs A & B, Lrvr, (oLo-Aonlrro (illV-T)rn (nrLoRru nuo AooLrscruls wrtr Motrnarr ro SrvrRr Asttrlu.G. Redding ' . R.E.Whlker*r , C. Hessel r , F.S. V i rant t3 , G.H. Ayars, , G. Bensch; ,J. Cordovai. S. Holmes: and P.M. Mendelmanr.t Llniuersit.v of Wasbington Scbool of Medicine. Seanle. WA; 2Auiron. Moun-tain Wew. CA; tNortbwest Allergv and Asthnta Center, Seattle, WA; tAllergt
ll:45 o.m. S24. Rracroctt'ttcttv luo Pnsslcr rNI0 IHE BRntrus or Entrnoroxrr'rs rr,ro cpe-0LrooNu(Lr0TtDEs Aorrlrr'rrsrrnrolrurRlusnLry ro Mrcr.P. Bourgui-ef-]on, M. Bisteau, S. VeenstLlt, P. Hern'r:.rncl, V. Henclerickx, M.Friede, Y. Lobet ancl M. Frrrrrcottc ' r 'GlaxoSntith l{line, Rixenscu't, Belgi u nt .
Luu*rl2:00 p.m.
SurmrnroPnrsrrurarrons 5:(Concurrent Session)
l0:30 o.m.
l0:45 o.m.
I l:00 u.m,
I l:15 o.n.
I l:30 a.m.
Auuvanrs AND IMMUNoMoDULAToRSMocler:rtors: Myron M. Levine, M.D., D.T.P.H.
Regency Bolhoom E
LIrt iu ers i t.1t o I' M cu"y I an d S ch oo / o f' M e d i c i n eRrian \W. Mahy, Ph.D., Sc.D.Centerc.fot' Disectse Control arul Prettentiort
S25. Dowt't Moouutton or Host It lrLnmmntonv Rrsponsrs rv Ratl(/o Anrn AoruovruL Grrur THrnapy.P.M.C. \7ong", X. Huang, J. Alnott, ancl S-rV. Chung.Tentple Urtiuercit.lt Schctctl c2f Medicine, Pbilaclelphia. PA.
S26. A NovrL Aotuvlltt FoRmuLntton (ottrutt'ttNo n BLocr (oporymrn wrrn RrvrRsr GrLlrrol (HaRlcrrRrsrrcsELtctn Louo Lnsttt. te toG Atlt t looy Rrspousrs Arrrn a SrucLr lutrcrrot ' t rr 'r Mrcr.C. Coeshott"', J. Blonder, E. Verdelber, K. Harrington ancl G.|. Rosenthal.RxKinetix lrtc., Lottist,ille, CO.
527. lHconpoRnnon or (D154 lruro SlVeno V[P Rrsuus rt l Rruucro rH vrvo lr, ,u,,rur,roGrNtory.L. Giaveclonil'2, S. Freyi, M. Velasqr-rillot, L. Parodir, zrnd V. Hodzrrar.t Sautbtuest Foundation Jbr Biomedical Researcb, and 2Sotttbtuest
Regional Primate Researcb Center, San Antonio, 7X.
52S. lmpnovtn Errttary or n Hrnprs SrrupLrx Vrnus oD Vlccrt ' tr ForLowrtlo lr,rcoRloRnloru or VrRaLEprropr luo Aotuvanr rt l Lrposomrs.L.H. Song*l, Sfl. Ernstr, G. Fr-rji2 andJ.P. Adler-Moore'.1 Cal Poly Unirerc ity, Po n t or m, CA; ) Molecular Erpress Inc., Los Angeles, CA.
529. (tt l t t l t Tnmn or Gnoup B StntptococcrL (onruelir VlcoHrs: Errrcrs or Aruru Aoruvnt' tr auoBoosrrn Dosrs on lmmutlocrHrcrry.L.C. Paoletti*1, D.-L. Kasperl, D. Molriner, D. Ambrosinor, and CJ. Bakeri.t ^ . ItBrigbam and Women's Hospital; 2Hantard Medical Scbool, Boston, MA;3Baylor College of Medicine, I{oustort, 7X.
S30. Ernrnunt Powotn llluuruliton 0r lNrtuiNzA Vnccrtlr wrrH (noLrnn Toxn luoucrs Mucosnr ltrlmuurRrsronsts nlo Pnorrrnon. :C. Erickson*, R. Endres. L. Payne. and D. Clren.Powderlect Vaccines Inc., Madison, W.
(ttntrnt Tntnr AND FTELD Stultts Regency Balhoom FMoclet atom'
?T, :,,il^;:::;,Y*? ;i|l!ri,,T::;,,?oXi,".-lX ,Yf;, u - r a r t ct p r eu e n t i c, t
S37. A Pulst l( Srurv or n DNA Hrpnrrrs B Vrccrnr rn l|ranHy Parrrurs Not'tnrsponsrvr ro Lrcrnsrollrplrrrrs B Vrccrurs: Ptrrruruny RrsuLrs.G.A. Poland*t, S. Rottinghausr, R.M. Jercobsont, ancl M. Iloyr.tMayct Clinic, Rochester, MltI;)Poutderyect Vaccines, Madisort, W.
l:{5 p.m. 538. ANttsoov Rrsponsrs ro Bovrtlr PrRartlrLuruzn Vrnus Typr 3 (PlV3) Vnccrnnrror'rano Hurrlnr'r PlV3lurrcrroH n Youruo lrrnurs.M.S. Lee'*', D.P. Greenberg', S. Yeh', R. Yogevt, K.S. Reisingert, -1.I. \farclj,
X}r"#,',i,i;:"i*:;,".|. August', v chenl, HB Mehtzrt, KL coelinghl
Slrttv luo ltutrturuoorntcttv or n 4-Dost SHoRt ItlttnvlL 0naL, Inncrrvnrro WHorr (rLL (nMpyLosnrlrrVncctut [o-nol,ttutsttnro wrtr Moorrrrt Escnmrcnu rorr Hmr-Llsrrr (LT*,,,0) Aoruvlli rr,r VoLururrrRs.D.R. Tribblet, S. Baqarr, F. Trespalaciosr, J.V. Sandersr, R. Valkeri, J.DClementsu, and D.A. Scottl.INar,ul Medical Researcb Center, Betbesda. MD; 2U.5. Arnt.y MedicalRe$earcb Institute of Infectiotts Disease, Frederick, MD; tAntex BiologicsInc.,
,Gattbersbutg, MD;aTulane Llttir,msitt Scbool of Medicine, Netu Orlearx, M.
Atlno,nt PrRs$Ttt'tct, PRP-Sptcrrrc lr,tmuur Mrruony & Boosrrn RrspoHsrs ro DTP/Hrs Vrccrur rru(Htrpnru ,Pnnlro wrtr a Nrw (ofirsn'nrroH Vnccrur DTPa-HBV-lPV/Hrs ar 2, 4 aHo 6 morurns or aor.
l:15 p.m.
T. Nolan*l, A. Altmanflt, G. Hogg', M. Skeljo3, and L. Schuerman'.t Royal Ch ild ren's Hosp i ta | : : LIt t i t'e rs i I.v o.[ Mel bo u r n e. At r st ra I i a :GlaxoSmitbKline, -iAustra lia € 'Belgiu ttt .
S4l. VlxGrH'i GLosnL Srnanov ro Drvrrop ruo EvaLunrr ru HIV Vrccrur, AIDSVAXTM.w. Heyntarctt S, irrud, P. B"r- an, ancl D. Francis.VaxGen, Inc., Brisbane. CA.
K. Choopanya*', S. Migasenar. S. Vanichseni ' . P. Pit isrrtt i t l rrrmr. D.Kitayapornr. P. Yodaner, K. Hiranrusr. J. Tapperor. and W. Hey'wardrtThe Banglak Vaccine Eualuatiott Group, Tloailattcl: :Vcn'Gett. Inc.. Brisbatrc. CA.
2;45 p;m;
3:00 p.m.
Svmposrum 4:
3:30 p.m.
4:00 p.m.
4:30 p.m.
5:00 p.m.
5:30 p.m.
Posrrn Gnoup l:
IIIII.{
.I
IT
Pt.
P2.
Iorrrr B nrnr/Posrrn 5rssror,r/[xHrsrTs
[ot,tnor or Mrt'trt,teococml DsEAsE By VA(crNAroN @Nlodelzrtors: Mylon M. Levine, M.D., D.T.P.H.
Lhtiuersitl' of Marylancl Scbortl o.f MedicinelJrudlev A. Pelk ins. M.D.Centerc.fbr" Disease Cot ttrol attcl Pret,er t ictrt
Grorlr Eptolturotocy or MrHrHoococcnr DrsrasrBtrc l ley A. Pc lk ins. M.D.Centerc.for Disease Cotilrol and Pret,entiort
Tttt UHttto Krleoom Exprnrrucr wru Mrlr loo(oc(Ar DlsrEsrDr rv id M. Sa l i s l> rny . M . l i .Dcpo t'l ntet tt ol- Haolth. LJtt ited Ki ttgdt tttt
Vnccrlr Clnorolrrs ron Gnoup B lVrrssram MmwanntsRino Rappuoli, Pl'r.D.Cbiron Vaccines
Plt'trt Dtstusstot't
Posrrn Srssror'r, Exntorts, AND RE(Epr0N
Crrrurclr Sruorrs AND DrsEAsE Eprurmroroey
Exhihit illllA
Regency Balkoom E/F
Exhibit HullA
Exhibrt HallA
PopuLlttor-Basro lrucrorucr Rlrrs or lnvnsrvr Purul,rocotclr lurrrnon rn (nttoRrH ru 7 (rnrrnsAcnoss (nHron, I 994-l 998.G. Bjornson. D. Sclreifele. and S. Halperin .Members of tbe CPS/LCDC Imnttr.nization Monitoring Program,Ac t i t'e( WIPACT ). Otta rua. OIrr. Canada.
Esitmnrs or Ronvrnus Asocrnrro Drnnnnm (RADI HosnuuzATlsns rn 0urrrr (ttrroneH From I985 ro 1998.B.Duval" ' r r ' . R.P. Buigues : '5, L. Rochettej , N. Boul iannerr, M.Douvi l le-F ledetLJ . P . Dery . and G.De Ser res t r .tlttstilttte Nrttional de Sattle publique du Quebec, Qtrcbec:: Llttite de Rechcrche en Santd Publique. Quebec:
tMittstdre de laSante et des Seruices sotciattx, Qu6bec,;
iCerttre bospitalier tlniuersitait:e d.e
Quebec ; t C o ntributed. equally.
P3. Rtsr tlctons roR Vltctrur FntLuRts rr,r (Hrronrtl Vlccrnarro wrrl AcrLLuLnn lno WttoLr-crLr Prnrussrs rr,rSrurolL.K. Lacombe, S. Pinchinat, A. Yam, K. Simonclon, F. Simonclon.Epidendolog).,arul. Prercttiott thtit. IRD Attonrpelliet; Frunce artcl Daka4 Senegal.
SorrnL lhntrls fvnrunrron ru rur Frnsr PHasr ll l HIV Vnccrnr [rrrcrcy TnrnL.L. Stoll"l andJ. Jenn:rnor.VaxGen, Inc, Brisbar'te, CA.
ELlSPOT Assavs roR EvlLunttou or Aurcrtl Spucrrrc Rrsponsrs rH HIV-l Vrccrrurro lr,rorvrourLs.M. Baileyt, E. KLrtal, E. Turkr, L. Galleyr, M. Scolesr, R. El Habilrr, p.
Caudrelieri, D. Schwart-zt, G. Ferrari5, D. Birxl, andJ.H. CoxttU.S. Militaryt HIV Research Program, Rctckttille, MD; zAt.,entis Pasteur,Marc-l,L'Etoile, France; iAuentis PAsteur, L-yort, France; '.fobns HctpleirtsflrtittercitJ,, Baltimore, MD; tDttke fhiluersity Medical Center', Dt.trbant,l\rc.
lmmunoorntcttv or Ftvr Dosts or lruacrrvarru l,f ircostcrff irun nrfirVArcNr rH HIV+ Susrrcrs.J.M. Vuola""r, M. Ristolzrr, A. Jzirviluomzrl, B.F. Coler, C.F. von Reyni.tNatiortal Public Healtb Institute, Helsinki, Finlancl; 2Helsinki LhtittersityCentral Hospital, Helsinki, Finland; iDaftntottth-Hitchcock MedicalCenter, Lebartctrt, l{etL, Hampsbire.
AH Urolrr oru rHr Ptt lsr I HurulH (LrrurcnL TnrnL or nH Epsrrn-Bnnn Vrnus Vlccrr,rr.J. Blraradwaj",T. Ngyuen, G. Lawrence, S.L. Elliott, A. Suhrbier, and DJ. Moss.Co*operatiLte Researcb Centerfor Vaccine Technolog)t, Queensland htstituteqf Medtcal Researcb, Bilsbane, Australizt.
furtutuza tllcctnlttoH AND SIRottt rN IHE EIDERr.y - A (olrrvruHrry-BAsED 0tsrnvnrroHnL Sruoy ru l(onra.B.'Chuno1, Xfl. Kim:, M. Kim2, H, Jeong2, E. Kim1, S. parkr.
P4.
P7.
tKon.yang tlniuersit.v Medical College, Nortszn, Korea; 2Korea LhilttersityMedical College, Seoul. Korea.
Pl0. IHt MrcHlHtsia 0F THt IHtRAptufl( EFtt(r 0r rHr (0MMrRoAL INA(lvArED VtRt0N VnccrHr Acrrusr HrnprsSrl,tprrx Vrnusrs I lruo 2 AT 0pHrAtMoHrRpEs AND GrrurnL Hrnprs.I. Barinslcv*r. E. Moldvinzeva:.tD.I.Iuatn'ouskv Institute of Virologlt RAMN; 2"VitafarmA" commercialJirnt,Russia.
Posrrn Gnoup 2: I tlu,t u t't oty p t N G A N D Vlcc t ru r D rv r Lo pl,t t t't t
Pl l. Expnrsstot't or luuuuotvprs Anrrcrtls sv MrNrircotocclL SrRarns 0srnrtlro rnol,t Parrrnis rn BnnzrL.E.F. Tl'rorn:rs Belor r, E.N. De Gasp'.lri"r'2.Ihttcuklade De Ci€ttcicts Fantzac?uticas rJa, Uniuersidctde De SAo Paulo;:Seqiio De Inutnologict, Ittstitttct Adol-fo Lutz Siio Paulo-9.P. Brctzil.
Plz. Stuov or LP5 lmuuruorvpts Epttopts or ,Vrtssrnla ttiltNltTtDts8 ru NnslL fu,u,runrzlrou rn l MousrMoorL.L .M.C . Carv r t l l r o Cor r t i n l ro r j . E .N . De Crspa r i ' ' r j .r$4Qcitt De Inttrttologia. lttstitttu Adolfu Ltrtz: 2Deparltnenlo de AtmlisesClirticas - Fctculdade de Ci6ncias Farntac2l.tticas - Lhtiuersidade de SdoPatrlo. Sao Patrlo-5.P. Brnzil.
Pl3. lmmunootutcttv or HtoltLv (otlstnvru Nussmu Mrnmanou Sunrncr PRorrrn lHnucro rN Ransrr ArrrnNlsrL lmmuurzATr0N tr 'rrTH Nlrrvr 0urrn MrMsnnNr VrsrcLrs.A.Seneme Ferrazl, E.N. De Gaspad*tr.tSegr)o De Imunologict, do h'tstittto Aclolfo Lutz; :Departnl,enIo de AnalisesClinicas - Faculclade de Ci€ncicts ForntacOuticas da Lhtit,ersidade de SdoPattlo. Sao Pattlo Brutzil.
R. Al-Torki*, S. Jiang, P.E. Kofoedl, P.Aabyr, :rnd M.W. Steward.Lottdort School of H.vgiettc €, Tropical Medic'itze, London, t/K; tProjecto deSaucle de Banclint, Bissau, Grutiea Bissatt.
Pl 5. THr Plutotl-VnLrHrrur Lrucocroru (PVL) or Srtrul,ncatcus Auluts Srrms lo rr (oRRrLlrru wtTH RrcuR-nrnr FuRuucuL0srs rN HttMANs Bur N0r wrrH lrurLnmunTony DtsEAsts iN (ATTIE.O. Nolte, H.E. rVeiss, H. \feiss, H.K. Geiss , H. Haag, H,G. Sonntag.Hygiene Institute, Heidelberg, Germanl , :
:Pl6. Drttcrrotl 0r Two N0vEr Arurrerrurc Pnorrrrus rH lrrs:umaura Mnron.
M.R. Mohammadyr. M. Zeinali t , A. Kariminiar, and S.K. Ardestaniltlrtstitute o.f Biochenistry and Biopbysics. Unittersity of Tebran, Tebran,Ira n: :Past u re Ittstitute, Tehran, Iran.
Pl7. Rapto DtttnmtruATr0N 0F (lnuolrr HLA:8.07 - trsrrrcruu $L Elroprs rRoM THr Wrsr NrLr VrnusNYgg Gruomr. :A.S. De Grootl r, C. Saint-Aubinl, J. Raynerr, W. Martini.tBt'ott'n Lhiluersit-V, Prouidence, RI; 2EpiVax, Ittc.. Prouidencc, KL
Pl8. (uucunlzattor or PotrtllaL Vnccrrur Pnorrrtls or M'ltostcrtntuM pARAtuB,:R(uL0s6.
_f. Mulleradnl, Y. Fishrn:lnr, A. Hovavr, I. Michzrll, R.G. Barlettar, H. Bercovierr.tHebreru Unfutercity,.[erusctlent, Israel: rLhtiuercilt,o.f hiebr"askcr. Lirtcoln, IYE.
Pl9. Mrurnoocotclr eroup A (ouucrrrs: Pnrcut,trcnL Sruorrs.A. Bartoloni. F. Norelli, G. Aver:rni, A. Gizrnno zzi, F. Di Pisa, E. Gallo, A.Martini, R. Paff-etti, S. Berti, R. Rossi, A. Bardotti, S. Ricci, V. Calinci. S.D'Ascenzi zlnd P. CostantinoChiron Vaccines, Siema, Italy.
DNA-mtomim lmmurrzlrror'r Mrrnoos wriH Hut'uru (yrol,rrolrovrnus (H(MV) GLycopnorrrru B (oB) ron rHrluoucttotl or NrurRrLrzrt.tc Ar,rlsoorrs ro H(MV ru BALB/c Mrcr.Y. Kwon, E. Park, S. Jeon, C. Palk, E. Hwang*, :rnd C. Cha.Seoul National (Jnitlersity College oJ'Medicine, Seoul, Korea
Snsrr HrcH Lrvrr ExpnrssroH or FonrreH Aurrorrus rR0M THr (Hnomosol,tr or SnrmourLrn rypHrMURruMVnccrHr Srurus.T.D. Terry'' and M.P. Jennings.Uiuersittt of Qneensland, St Lucia, Qneensland, Australia
Evntunttoru or rSamouuta Pruoorurcrry lsLnuo-2 (SPl-2) Muurur ot SALMINELLAtyplt As n VaccrnrVrnon ru Mrcr.T Bellaby, R. Strzrtford, N. McKelvie, S.M. Chatfield, F.R. Brennan and S.A.Khan,MiEroscience Ltcl., Berksbir"e, UK.
Pf3: (runlcruunuou or Pnorrcrrvr IMMUNE Rrspotlsr Errcrrro By ATpHAVTRUs Rrprrcons ExpRrssrtlo rHE HrRpEsStupux Vrnus lvpr 2 ( l |SV-2) GLvcopnorrrr l H (cH)-GucopRorErN L (c[) [or ' lpLrx.D. Longt, R. Natukr, J. Kowalskil, J. Strasseri, S. Gangollit, E. Mishkinr, D.Bernsteins, and T. Zambt.
,,' a.gts Research, Wyelh'Lederle Vaccines, Pearl Riuer NY; 'tCIIil[C, Cincinnati, OH, . . - , t , , , , , , : . : , , , i l : : ,
P24. frrtcls or (oNrusnrrol,r{nrmrsny oil lMMUN0r-0GrcnL Rmcrvrrv AND EprT0pEs ExpRrssrr rH Tvpr lll Gnoup BSrnnrococclL Poryslccnnnr or.C,H, Lee, N.:,Concepcion, G, Arakere, and C.E. Frasch.DBPAP, ovRn,.,,CBER,,pill i,betlcesda, MD.
P2r.
f,.l.ldfrl11rf.fqqd
P26.
P27.
Tnr Usr or Iomptrx Sunrncr Anrroms or SaLaroHnLl, EstHrRr*ru, Pnorrus auo Psrunol,touns ru luorRrcrH rmlcoLurr t'tntror'r Assay.L.V. l ' r r rk l ronrcnko" ' . S . l . B ic lnenko, M. l . Gnr t rnan.I t tst i l t t l t , t f 'Epir{ t , t t t i r t lct ,q),rutcl I t t fbdiotts Diseascr. Kl , i r , . t lkraine.
DtvtLopmrul 0F (oMILEX Sunmcr Anttorus 0r SArMoNnrA, EcHrRrctn, PRorrus lno Psruoonoruns.V.N. Perk l ro lncnko" ' . M. I . G l r - r tmrLn. L .V . Parkhonrcnko, S . I . Anc l l ianov ,A.M. S l tc l re lb inskr r .I t t s t it tt t e o.l' Ep i cl ent i o / og.lt ct rt cl In fe ct i o t t s D iseot s es, K1t i 1,, Llkra i n e.
Ttt Drrrrusr 0F IMMUNt Stnn to IotupLrx Sunrncr Ar'rrrcrus 0r [s(]rtRt(tllA, SnrmonrLLt, Psruoolloruns nuoPnorrus Urlrn Exprnrl,trNrAI lNrE(10N.M.I . Grutman*. L . \ / . Pulk l romenko, V.N. l )a l 'k l ronrenko.Irtstitute of' EpiclenilologU ancl InJectic,ttts Diseases. Kyit,, Ukra i ne.
Vltcrr,rrs AND VA(cNE Cntrurulrrs
A Srnuoano Nomrt'tcLnruRr ron Vnccrur AssnrvrnrroH.ts.G. \Weniger.National Intntunization Program, CDC. Atlanta, GA.
THr Jorr 'rr VnccrHr Acoursrrrot ' t PRoonnm r0R Bt0DErENsr Vnccrrurs.V. Peierson*, L. Van de Verg, D. Steele, D. Danley..foirtt Vaccine Acquisition Progrant, Fott Detrick, MD.
ItvttrluutzlttoN wtTH DNA (otlstnucr or n Prprror Mrmroropr lnourrs a (noss-Rrlrlrvr anrr-ftnaoHy-DRAIT ANItB0Dy trirHt(H BTNDS ro }|IV-l ErvrLopr Grycopnorrrn lruo ItqHmrrs rnr Aunrsrou 0r [)ril-DRri l( CE[rs r0 AN ENV Tnlusrrcrro (rLL Lrtr.B. Monzavi-Karbassi, S. Shamloo, P.Luo, G. Cunto-Amesry, D.B.Veiner'. T. Kieber-Emmolr.s.I niuercit,v of Pentn.vluattia. Philadetpbia. PA.
A Prpttor Mtuntc 0F A PNtuM0(0((At fnpsuLAR PoLvsnccHlRror Pmurg r0R AN,ENflANfrn Rrspor{sr rornr 0nrorHlL Atlrrcru.G. Cunto-Amesty. P.Luo, A. Leesr, T. Kieber-Emmons*.LIt t i t'e rc itv ctf Pe n t rc.v I t w n ia, Ph i I a delpb ia. PA: t B i ostry ex t t s. In c .,Rockt'ille. MD.
Ptpttootrl t l t tcs Stttt tro rnou PHner DtspLav It lRnnrrs lruoutrn NrurnnLtznrs Anrrsooy Rrspollsr
lmmuur Rrsrousr ro 0nnL Anl,trursrrnro AurovnccrHrs.A. Bindes'alcl, O. Nolte, H.E. W-eiss, H. Veiss, H.G. Sor-rntag.Hygiette Institute, Heidetbery. Getnta n.1,.
Drnrrro Morrtumn [voLurror'r or Vnccrr'rr Aurrertls.S. Bass", E. Karrer, A. Goel, R. Lyonst, et al.Maxrygen htc. Redtt'ood City, CA: ILhtit-ercity oJ'lYeu'Mexicc,t,Albuqueryue, lVM.
llitmunoroe rGL AND Broroe tcar Rrsponsrs T0 lMMUNtzATt0N
P35, Tnr HIV-l Vpu Pnorrrn ruo Grtlrnarroru or [DB-T (rLL Rrsporusrs rn Mrcr.B.P. Nayak and A.M. Jabbal.Ernorry Llniuercit!, Atlantt, GA.
P36. EtHnrcro lmmuHr Rrspousts ELtcttro sv DNA Vaccrurrotl wrrH HIV cpl20-(30 Fusron (orusrnucrs.T.D. Gleenl, Y. XLlr, D.C. Montefiori.r, H.L. Robinson2, and T.M.Rossl.lEast Carolina Universiry, Greenville, NC; rEmory University, Atlanta,GA; 'rDuke fh'tiuercit.y Dtuhant, NC.
P37 . EptutRl,trL Poworn lmt'lu utznttotl wrtr H lV cp I 20 luou crs Bortt H uM0RAL ruo (rLLuLlR lt'ulur,rrRrspotlsrs.C. Zuleger, J. Osolio, D. Chen, L. Payne.Potudedect Vaccines, Madisort, W.
P38. :THr RoLr or T (rLLs rru VrnrcrrLr-Zosrrn Vrnus (VZV) Prrnoornrsrs.C. Ku, E. Butcher, and A. Aruin.Sta nfu'ct [Jt tittersit-y, Stanforcl, CA.
P39. tvoiurron or EHvrLopt-SptctRc Anrrsoov Rrsponsrs Asocrnno wTH Tttr DwrLopmrm or EuouRruo BnonoryPnorrcnvr luuulrrw.rn Motlrtys luocuLlrro wm Anruunno SlV.J.L. Rowleso, K.S. Cole. M. MLu'plrey-Corb, and R.C. Montelaro.Uniuetsit.y of Pittsburgb Scbool of Medicine. Pittsburgh. PA.
P40. A (outuclttu Plrtt toulvtrus-[rxr PlnrrcLr Basru VlroHr Grnruirs HroH Trrrn AurorHrrsoorrs roTNF-"" lHl PRorrcls Aoalnsr ArrHnrrrs lr,roucrrou ru n Mousr MoorL.B. Cluckerian, D.R. Lowy, and J.T. Schiller.Natiortal Cancer Institute. Betbesda, MD.
P4l. Trr Exrnrssror AtlD R0rr 0F rf lr MuRtNE (nulorrnr, l-TA( ru VlRus lurrcrroH.H.H.R Flamilton*, S. Mahalingam, I.A. Ramshaw. S. Ramsay. S.A. Thomson.Tlse.fohn Cirtain School of Medical Researcb. The Australiutr NationalUniuerc it,y, Ca nberra, ACT, At r st ra lia .
r+i,tio.d#
Posrrn Gnoup 6:
P42. THr Errrcr or lurLunza luuur,rrzuron ou (YP3A4 Acrrvry.M.S. Hr ry r rc 'y ' . .1 .M. B t rc l t .I' r t i rt' t's i t.t' (y'' W r\('ul1.\ i t t 5t' l.t t rtl o.l' Ph a r n t cr c.'1,. -1[t t t l i so t t, W
P43. THr Assocrnlor'r or TAPI nno TAP2 PoLyrrlonpHtsr,rs aNo ANrtsooy Rrspousr ro Lrvi MmsLrs Vlccrur VrnusN. Dhinnn*, I.G. Or.syannikor,:r, N. Pinskry, R.A. Merkant, R.M. -|acobson,
P44. [oupnnrsor or Aoruvrnr Errrcrs Errcrrn sv [lLcrur\4 ProspHnrr NlHomnrrrLrs Vrnsus ALuu.Q. He*, K. McCurn, T. Molcol, S.l.D. Bc'l l .BioSante Pharmaceuticctls. Srnyrnr.t, GA.
P45. PoLyrsrrR MrcRopnnrrcLrs ns l Vlccrur DrLtvrRy Sysrrm ron BnucrrLosrs.C. Garntzo*t , M. Muri l lot , M.| . Gl i l lo ' r , . f . Rei61, C.M. Merinr, M.Barberinr, M.M. Gonit , J.M. Blascor, J.M. Irachel.lflrtir-'ersit.y o.f liauarrct. Pctntplorta-Spctirt: :Artintal Health LInit.Za ra,qt za-Spd it t .
P46. lroucrroN or (D4lruo (D8 T (rLL Rrspor,rsrs Usrtlc Arurcru EucapsuLlrro ru Gnlrrn-[roNDR0rTrNSuLrnrr MrcnospHrRrs.D. Ler in ' " . E . l vz r rd r r l rnd R. Az l t r r l i .Ort Braucle College, Karnilel. Israel.
P48. Drcnmsro NoN-rvpmsu HrruopnrLus TNFLUENzAT (NTHr) Itlrrcloru FoLLowrHe P6 [rposolllrVnccnniron or Wrntlrrue Rnrs.N. Sa ic l t . $ / . Erns t - . S . Yeg iyants r . L . Songr , G. Fu j i i j , anc lJ .P . Ad le r -Moc-lt 'c i .tCal Poly, Pontont, CA; 2Molecular Express Inc., Ios Angeles, CA.
P49. MucoslL AomrHrsrurroH or TonLLv SytlrHrrrc Lpoprprrors ltrrnouT Ao:uvnur lHoucro Sysrrurc h,u,luurRrpouses.L. IlenMohamed"r, Y. Belkaidr, E. Loing-J, K. Brahimiz, H. Gras-Masse-r,and P. Dru i l l re j .t Ced a rs-S i t t a i Med i ca I Ce t fier. Los Angeles, CA: : Past ert r In st i t t t te,Paris, F'rance; th'tstitwt de Biologie and Institute Pasteur de Iille,Ft'a nce.
serGsG#CT#;
GGGCiTcrGcrGCltC|CGrddcrcrdCll5r,l;rl;!I6drl
P50. THr Nrw S.rntHntt (ompouruos 0M-294-MP ar'ro 0M-294-DP lr'roucr (rLLuLan ano HurnouLRrsrousrs rlt 2 Munrrur Vnccrtr MoorLs.G. Corr':rclifl ', D. Rivierr, O. Mltrtinr, G. D:lvies''., -1. IJltLler..rLlniuercit_y of'Lctusartrrc. Epcr/in,ges, Stt,itzerlartd: )(Init,ersit.), of'Ofiectns, Orleans, F-t'cutce; )OLI PHAR\IA. Mew'irt/Ga'tet'cr. Su'itzeflattcl.
P5l. THr Nru Auuvlul0M-174 Illoucrs Mtcnutot' AND MAruRArotr or DnoRrrrc [rLLs rr'r Vrvo lru rHrMousr.I3. Pajakr, V. Garzcr, G. Davic-sr"', M. Mosert, C. Chiavzrrolir.tLlrzittetsiti Liclre cie Brtxelles, Gosselies, Belgium: )Ol.I 7IIAR\4A,Meyri n/Ge n e t, a, Su.t it zerlct n cl .
P52. luuuuosttnoto Tntntl,trtlt 0F AGrD Mrcr lr Vlccrurotl lr'rcRusrs ANrrsooy Rrspor,rsrs. ano ELrcrrs nlnl fin2 PnorrLr RrsrMsuNG IHAT 0r Y0uNG Ar,rrr',uLs.Enioutinat. It.|. Rigg"'', R.A. D:rynesr r.t(htiuersit-t, oJ'Ltah, Salt Lake Cit.y, W; )Hollis-Edett pbarntaceuticcrls,
Sart Diegct, CA.
P53. Ar Aoruvnur-ANrGrN M0DEt ron PLlr'rr-msro MucoslL Vaccrrur PRoouclor,t.F. Medina-Bolir.zlr' 'r, R. Vrigl-rtr, D. Sentzr, T. Wilkinsr, \X/. Petli, -lr.r, andC. Cramerr.t Virginict Tecb ;
2 Lhtit,ersit-y o.f Virginia.
P54. InrLurnzl Vtnosours ARt AN EtnctNt Druvrnv Sysrrm ron RSV F Altrrorr,r HumonnL AND (rLr-MEDtATEDlut'luuttv.M.G. Cusi*, R. Zurltriggent, P. Correzlle, M. Valassinu, P.E. Valensin, R.Gluck.Llniuersity o.f Siena, Siena, Ital-1t; /Szlz'sl Seruun ancl Vaccine htstihfieBenze, Berne, Sttitzefland.
WtoursoRY, Arnrr 25, 200 |
7:00-8:00 o.m.
7:30 o.m.
Svmpostuttl 5:
8:00 o.m.
8:05 o.m.
8:25 o.m.
8:35 o.m.
8:55 o.m.
9:05 o.m.
9:25 o.m.
9:35 o.m.
Nrw Appnol(ttEs T0 Vaccrt'lr Drvrropmrt,tT @
RrotstRlrot't
(ot lrt ' truuL Bnrnrrnsr
Fayu - ftegency Eslhaom E/F
Exhibit HallA
Regency Ballroom E/FMoclerators: Glegory A. Polancl, M.D.
A Ia.vc) Cl i t t ic a t td Fot r t rrlatiuttN . Reg in l Rab inov ich . M.D.Progra m .for App rop riat e Tec b nolog.V itt Hea lth
lrutnooucrror'rN. Regina Rabinovich, M.D.Pt'r,tgrnnt frtr Appt'oprialt,Techttologv uttd Health ( PATH)
Ust or NovrL Mnss SprcrnomnRy Trcnuorocy rt l Vncotlr DrvrLopmrrurGregory A. Poland, M.D.Mcryct Clinic and Foundatiort
0utsttot'ts lr'ro Auswrns
Ust or Mrcnocnrp Annny nt ' to Grrur Expnrssroru TrcHlroLooy rN Vlccrrcr DrvrLopurnrMalcel A. Belu'. M.D.Mccill Lhtittercit.y
Halifax Medical CertterDavicl E. Swayne, D.V.M., Irh.D.tJ.S. Deparln.tertf cl- A,qri c ult ure
luuutltzlttot't or HPV+ Pltttttts wttn Hrcn-Guor AtlaL Dyspusra Usrruc n MrcRospHrRr ErucnpsuLlrroDNA Vacrrur (ZYCl0l) RrsuLrs rH HPV Sprcrnc luuunr Rrspousrs.M. Matijevicr, B. Klencker, J. palefskyr, M.L. Hc-clleyr, and R.G. urbanr.t zYcos lrtc., rexington, MA; 2 fhtittercitJt o.l' catiforhia san FranciscoCancer Center, San l"tancisco, CA.
Tr tRnprutr c Vlcc r uarro r'r Acnr tlst Atzn rttrlrn's D rsrnst.K. Ugenr, C. Dickeyr, M.N. Gordonr, ancl D. Morganr.tDept. of Med. Micro. And Intmttnol. and 2Dept. of pbarnmcolog1v, LhthprsitloJ' Sottth Florida, Tampa, FL.
RtstoRnitotl or I FuructtoHnL Ar'rrr-HlV (D8 lmr'lur'rr Rrsponsr rr'r HLA-A2 HIV-lr,rrrrrro Parrrlrs Tnmirowrrn a oao/poL, rruv/nrv DNA Vaccrur.J.D. Boyerl, G. Silvestrir, I.S. Gourleyr, C. Kangt, M. KamouD,, R.Ginsbergr, R.R. MacGregor2 and D. Weinerr.ruttirlersit.y of Pennsyluania: 2Hosprtal of tbe Lhtittersitlt oJ'penns.ylua-nia, Pbiladelpbia, PA; .tWyetb Lederle Vaccines, pearl Ritter, Ny.
PtttttHlclL Stuov or Dtruontttc (rLLs PuLsro wrrH ALpHI-ouA(rosyr(ERAMror nuo TumoR-sprcrrrc prprrorls.Aurr=uucrn VaccrHr.M. Kataokar. K. Lyerly-. and Y. Dengr.'Eastern virginia Medical Scbool, Ivorlfolk, vA;2Duke Llniuersity MeclicalSchool, Durbam. NC.
lurrH| 2:00 p.m.
SunmrnruPnrsrurnnolls 9:(Concument Session)
Nrruu-FnrrModerators:
Drnmar Vltgrurroll Regency Bollroom FDavid A. Neumann. Pl t .D.Nat i o n a I Fo u r t d a t i onj fo r Infec t io us Dis e as esHarriet L. Robinson. PIr.D.Emorry tlniuersit-v
dldddd
I l:00 o.m. s47.
I l :15 o.m.
I l:30 o.m. S49.
I l:45 o.m.
Sarttv atlo lmmuuoorntcttv or a Tnanscunr{r0usry AomrrursrrRro PRororypr TRnvrLrR's DntRHrnVnccttlr (oruststtttc or Hrnt-LlsrLr Toxrru (LT) ltlo (S6 (oLoHrzlrrot.t Flcron or EnrrRoroxrornrcEscnru cur t corr ( ETE().F. Guererial, L).N. Taylorl. E.R. Hallj, D. Scotti, M.K. \Xblil, F.|. Casselsl,
f . J . R r l r t ' r ' t s : . C . l l . A l r i n g r . , G . M . G l e n n r .' WRAIR. Silt 'at' Spt'ittg. -l [D:
-'Iotttai Cotp.. Washiugtctrr. D.C.:
'NMRC.
Si l t ' c t 'Sp t ' i tqq . MD.
EprornmnL Poworn luuur,rrzlrtoru wrtH (ot,lvrurronnL Ptorrru Vlccrnrs.L.G. Payne":rnd D. Chen.Pott'rlct.' lt,cl I uccittes Ittc'.. Matlisott. W.
MncnorLux@ Srn PntcH TtcrruoLoov: A PnncrrclL lrurnacurnNrous Vlrcurrou Sysrrr,r.J.A. Matriano"', M. Cormier', J. Johnson, \7.A. Young, M. Buttery, K.Nyam,e n c l l ) . F . D r d d o n a . .ALZA Cotporaliott. .Vcttttttuitt Vieu'. CA.
I t Dendritic cell subpopulations: biology and iherapeutic use.
I J J Banc.hereau. J F.ay, M. Mohamadzadeh, B. Pulendran, and. K. Palucka.Baylor Institute lor lmmunology Research, Dallas, TX
Di constitute a complex Jystem ot cells which induce, sustain andregulate immune responses. Four stages of development have beendelineated including 1) bone marrow progenitors, 2) precursor DC whichare patrolling through blood, lymphatics as well as lymphoid tissues; 3)tissue-residing immature DC; and 4) mature DC, present within secondarylymphoid organs. The DC heterogeneity is reflected at three levels: 1)precursor populations, e.g, in humans two subsets of DC precursorscirculate in the blood: CD14+CD1 lc+ monocytes and LlNnegCDl 1c-ll-3Ralpha+ precursor DC; 2) anatomical localization; 3) function asdiscussed below, and 4) the final outcome ol immune response, i.e., theinduction of tolerance or immunity. Several key features of DC may behighlighted: 1) The existence of different subsets that share biologicaltunctions, yet display unique ones such as polarization of T cell responsestowards Typel or Type2 or regulation oJ B cell responses; 2) Thefunctional specialization according to their differentiation/maturationstages: i) ability to secrete large amounts ol pro-inflammatory and/or anti-viral cytokines at their precursor stage, ii) high antigen capture capacity attheir immature stage, and iii) ability to activate and modulate T cellresponses at their mature stage; 3) The plasticity of dendritic cell funclionswhich is determined by the microenvironment (eg: cytokines) may maniiestas i) the final diflerentiation into either dendritic cell (enhanced antigenpresentation) or macrophage (enhanced antigen degradation), ii) theinduction of immunity or tolerance. All these properties permit to developstrategies allowing lor manipulation of DC subsets both in vivo and ex vivoto induce a desired type of immune responses.
| 4 Global Epidemiology of Meningococcal Disease
Bradley A. Perkins, M.D., Chiel Meningitis & SpecialPathogens Branch, Centers for Disease Control &Prevention, Adanta, GA
Neisseriameningitidis (the meningococcus) has been recognized asa cause of invasive bacterial disease occurring sporadically and asepidemics for almost 200 years. Although theri has been a grear dealof research and licensed vaccines are available, improved control ofmeningococcal disease remains a substantial public health challenge.The epidemiology of N. meningitidis infecrions will be reviewed riirhparticular emphasis on how this impacts current and future strategies forprevention.
r5 The United Kingdom Experience with Meningococcal DisesseDavid M. Salisbury, M.B.D€partment of Health, United Kingdom
During the 1990s, there were i[portant changes in the epidemiolory of nrningococcaldisease in the UK. The overall incidence increased, the proportion ofcasas reported assepticaemia raths than rEningitis ircreased, md there was a significant shift to higherprcpqtions ofgroup C case6 occuning in adolescents/young adults, Since the latter caseshave high€r fatality rates, the overall burden of deaths has increased. Estimates for C;roup Cwere for arornd 1530 cases armually with 150 deattrsIn 1994, the Departrnnt of Health identified nrningococcal vaccirp research as a priority andextra resources were directed towards the accelerated development of Group C conjugatevaccines. The Public Health Labcratory Service coordinated the work, with otlrcrftvernnEnt funded agerrcies ard the vaccine manufacturers. In 1997 extra resources wereprovided to accelerate the vaccine studies. Studies on imrnunogenicity and rflctogenicitywse completed in 1999 and tlree vaccines were licemed in 1999 and 2000.ln autum 1999, all first year university/college students were offered imnnrnisation usingthe already available plain polysaccharide A+C vaccine, either through gersal practitiorersor on arrival at univ€rsity/college. Estinntes suggest that covuage was 70-757o.Starting in mid-November 1999, a school-based programnr for young people aged 15 up to18 was irnplerEnted using the new conjugate Croup C vaccirn. Coverage was higfr; therehave been very few reports of serious adverse events. From the begiming of Deember i999,the rEw conjugate Group C vaccine has been provided for infants at the sane tirE as each oftheir DTPiHib doss; chil&en aged 13 months received one dce with their MMRimunisations. Children >4 montbs ard <1 year had two doses. Ttr progamnr has now :been exparded in line with vamine supplies so as to offer immunisation for all children <18 ,years within tle space of one year. The total target population is 15 million. Pre-erdsitrg ,:,:heightened surueillarrce for nrningococcal disease is now demonstrating that as inrilrnisationis corpleted in each age band so there is a &amatic inrpact on Croup C meningococcaldiSeaSe. I ;;.1:.:::1,1 r,:,,
Reverse vaccirclosr &d the idcntification of velifE f€ndidates
for group B Nerseria meningitidist6R. Rappuoli, M. Piza md C. Orandi; IRIS, Chircn spA, $iena" Ira.ly; E.R. Moxon.Moltrulil lnfecrious DiseN Group, Uniwnity of Oxford, UK; H- Tettelin, C.M. FrMmd J.C. Venrel The Insdtuc for Genmic RestrclL Rtrkville. MD. USA.
, , , , ' t : '
Meningocccal reningir.is md scpsisrare,:devastaling diseases &at:,*ah kill ehildren andyoung adults within hom despiE the availabiliry of iffective antibiotics. TIE disarcs trecausd by Neisseria menin6itidh, a Gffin€gativs capsularcd brcterim which hu benclassified into five nEin pathogmic:scrogroupq {A; B, C. Yr and Wl35) orl tlisbasis of thechemical composirion of distirctive capsultr polyscchsides. Vecires agaimt sogoupsA, C, Y and 1{135,:,,i!arE dcletq@ !o rhe l960s by uq4g the;,pm-ified;capsulcpolysacchtride as antigen. Sffind gemradon, conjugaled vrcines m now beinginroduced. This approrch could nor be usd for rcmgrcup B b€BN the capsultrpolysaccharide is a polysialic aiid;::,idenri6al::in,::srructure,,,tn C :self'anaigen. 'iAs acmscqwnce, today thcrc s, c no f,ll€ctiye t$dtelr:,,av*ilable for rhe ,pleiention ofwgrcuF B N. mmingiridis (McnB) direac. wtich is rcsponsible approxitrEtely 50% ofall casei. To identiS novel vrccine candida&s, we deFrmired the gwm seqrenre of thevinlenr sFain MC58. DNA t"gmnE were malfEd to idem.ify open reading ftffis(ORFS) 1*rat potenrirly encoded mvel surfaceexposed or exponed Plot€im. The gffircre exprespd, $e mombinant ploteios werc purified and usd Do itruia mice.Immure sn wcre dEn lcated in ELISA ild Flresffie Activat:d Cell Soner ffACS)ilalyss !o de&ct proteins that rere prc$nt on de surfrce of rhe brcrerim. In addition,th€ fusnune sera were tcsred for brcteriridal activity, d this assy coFelaEs withprotetion in hms. Cosputcr ffining idcndficd approxinarely 600 proeins. Of these350 weF expressd s Ercherichia coli and 6€d to imunia oice. The smiling alloweddiscovering 85 rew surface-exposed trcteim, 25 of which indred bactericidal mtibodies.Mst of the newty idenrificd prceins re **f*4 in sequece eross a sd of strainsselect€d to rcprcsent the squence diversiry of the group B rreningococcu popularion.
A Nasal Proteosome Influenza Vaccine using a Baculovirusra.r 1 Hemagglutinin Induces lmproved Mucosar and systemicJJ I lmmunity.
DH Jones*, F Allard, s rran, M plante, J Gauthier, K Torossian, GWhite, GH Lowell & DS Burt. Intellivax International Inc., Canada.
Recent events, namely the difficulties of meeting the demand for egg-derivedinfluenza vaccine for the 200012001 season and potential pr66ems inmanufacturing egg-derived vaccines against potentialty pandemic strains ofinfluenza, emphasize the need for alternative soures of antigens for fluvaccines. One potential source of the protective influenza hemagglutinin is therecombinant protein (rHA) cfoned and purifted from a baculovirus expressionsystem. rHA can be isolated with >95o/o purity and in clinical trials was welltolerated and immunogenic following intramuscular (i.m.) injection. However,higher doses were needed to induce responses comparab6 to those elicitedby cunent licensed vaccines. Furtrennore, the T-cell responses appear to beof type 0 phenotype, and mucosal responses were not induc,ed. Pioteosomeshave been shown capable of qualitatively and quantitatively enhancing theelicited responses to intranasally administered split flu antigens. We havjthusinvestigated the possibility of enhancing the immunoglnicity of rHA bycomparing in mice he immune responses elicited by a proteosomeformulated, inhanasally (i.n.) administered rH,A (Pr-rHA) wittrthose induced byi-m. or i.n. administration of rHA. The results demonsbate that in contrast torHA given by either route, i.n. administration of Pr-rHA induced mucosalresponses in the respiratory tract, as well as higher serum lgG and Hl titers.Also in contrast to rHA alone by either route which induced the release of bothIFN-y and fL-5 from virus-stimulated splenocytes, i.n. pr-rHA induced therelease of IFN-y exclusively from restimulated splenocytes. These datasuggest that a nasally administered Pr-rHA vaccine 1) enhances specificserum antibody responses to levels comparable to those elicited by currentinjectable vaccines; and 2) elicits T-cell responses of the type 1 phenotype.]hese data suggests that vaccines comprising proteoiome
-forrnulited
baculovirus HA induce immunity capable of conteiring protection againstinfl uenza virus infection.
Fourth Annual ConferenceABSTRACTS OF SUBMITTED PRESENTATIONS